Perspectives on Ensifentrine and Its Therapeutic Potential in the Treatment of COPD: Evidence to Date.

Article Details

Citation

Copy to clipboard

Faruqi MA, Khan MMKS, Mannino DM

Perspectives on Ensifentrine and Its Therapeutic Potential in the Treatment of COPD: Evidence to Date.

Int J Chron Obstruct Pulmon Dis. 2024 Jan 3;19:11-16. doi: 10.2147/COPD.S385811. eCollection 2024.

PubMed ID

38188891 [ View in PubMed

]

Abstract

Ensifentrine is a novel inhalational phosphodiesterase (PDE)3 and PDE4 inhibitor which improves bronchodilation and decreases inflammatory markers by acting locally on the bronchial tissue, with minimal systemic effects. Both preclinical and clinical trials have demonstrated benefits of this therapy, including improvement in lung function and reduction in exacerbations. This therapy is currently under review by the US Food and Drug Administration with a decision expected in 2024.

DrugBank Data that Cites this Article

Drugs

Ensifentrine

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Ensifentrine	Phosphodiesterase 3 (Protein Group)	Protein group	Humans	Yes	Inhibitor	Details
Ensifentrine	Phosphodiesterase 4 (Protein Group)	Protein group	Humans	Yes	Inhibitor	Details